Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

37.9

Other product sales

Other 0.9 1.4 3.7 8.6

Contract manufacturing 4.3 6.1 25.7 20.8

Total product net sales 224.6 203.8 888.2 751.9

Other revenue

Other non-product revenue 3.1 2.6 11.4 2.6

Total revenue $227.7 $206.4 $899.6 $754.5

WARNER CHILCOTT LIMITED

SUMMARY OF SG&A EXPENSES

(In millions of U.S. dollars)

(Unaudited)

Quarter Ended

Dec-31-07 Dec-31-06

Advertising & promotion $15.5 $17.0

Selling & distribution 22.8 20.1

General, administrative & other 18.7 17.8

Total SG&A $57.0 $54.9

Year Ended

Dec-31-07 Dec-31-06

Advertising & promotion $81.0 $72.0

Selling & distribution 89.5 75.8

General, administrative & other 95.3 106.1

Total SG&A $265.8 $253.9


'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Texas , Dec. 16, 2014  Vermillion, Inc. ... focused on gynecologic disease, today announced the next step ... a premier bio-analytics solutions provider with the naming of ... President and Chief Executive Officer, while current Chairman of ... continue to serve as Chairman. These changes are effective ...
(Date:12/17/2014)... 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a primary commercial focus on China ... Type C meeting with the U.S. Food and Drug ... in February 2015.  During this meeting the Company will ...
(Date:12/17/2014)...   Synageva BioPharma Corp. (NASDAQ: ... rare disorders, announced today its presentation at the upcoming ... San Francisco, CA. Sanj ... present on Monday, January 12, 2015, at 9:00 a.m. ... live and may be accessed from the "Webcasts & ...
(Date:12/15/2014)... PETACH TIKVAH, Israel , Dec. 15, ... BCLI ), a leading developer of adult stem cell ... Brainstorm Cell Therapeutics Ltd. was awarded a grant of ... Office of the Chief Scientist (OCS).  This is the ... grant support from the Office of the Chief Scientist, ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... Satisfies initial listing requirements with NASDAQ; Stock ... which extends cash runway while focusing ... Aug. 21 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (formerly ... "Company") announced that the Company has completed ...
... Management and Supports Best-Of-Breed, Clinical Environments - Without ... ... Software Upgrades, OAKLAND, Calif., Aug. 21 ... and information,systems, and Epiphany Cardiography Products, introduce CardioECG 3.2,multi-modality, multi-vendor, ...
... Netherlands, August 21 Hoya,Corporation,s Vision Care Division, a ... today that it acquired Dioptra CZ a.s., one of,the ... Dioptra has a long and rich tradition in ... and Dioptra have worked together under an,exclusive arrangement since ...
Cached Biology Technology:Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 2Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 3Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 4Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 5Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today 6LUMEDX Introduces Advanced Multi-Modality, Multi-Vendor, Web-Enabled ECG Management Solution 2Hoya Vision Care Expands in Czech Republic 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... has been implicated in heart disease, weight gain, and diabetes, ... a source of chronic stress, present a challenge even for ... some species somehow manage to survive, and even thrive, in ... Yuri Springer in the November issue of the American ...
... Medical Center in New York have confirmed that Homo ... a descendant of healthy humans dwarfed by disease. Using ... researchers determined the "hobbit" to be a distinct species and ... of the study appear in the December issue of ...
... that can boost fuel efficiency without sacrificing safety and durability ... tires could help add an extra mile or two per ... the cover story of the current issue of Chemical & ... Editor Alexander Tullo explains that rolling resistance the friction ...
Cached Biology News:The benefits of stress ... in plants 2'Hobbits' are a new human species -- according to the statistical analysis of fossils 2